Print page Resize text Change font-size Change font-size Change font-size


 

Benefit- Risk integration and representation

REPORTS AND DATABASES

Recommendations of the IMI-PROTECT Benefit-Risk


Hughes et al, Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines, Nov 2013

Methodologies for benefit-risk assessment of medicines

Review of methodologies

Mt-Isa et al, Review of methodologies for benefit and risk assessment of medication, May 2013

 

Wave 1 Case Studies

Rimonabant

Juhaeri et al, Benefit Risk Wave 1 Case study report Rimonabant, Oct 2011

Mt-Isa et al, Supplement to Wave 1 Case study report Rimonabant, Oct 2011

Telithromycin

Quartey et al, Benefit Risk Wave 1 Case study report Telithromycin, Feb 2012

Efalizumab

Micaleff et al, Benefit Risk Wave Case study Report Efalizumab, Feb 2013

Micaleff A et al, Supplement 1 to Wave 1 case study report Efalizumab, Feb 2013

Phillips et al, Supplement 2 to Wave 1 case study report Efalizumab, Feb 2013

Natalizumab

Nixon et al, Benefit Risk Wave 1 Case study report Natalizumab, May 2013

 

Visualisation methods for representation of benefit risk assessment of medicine

Review of methods

Part one

Mt-Isa et al, Review of visualisation methods for the representation of benefit risk assessment of medication, Feb 2013

Part two

Mt-Isa et al, Review of visualisation methods for the representation of benefit risk assessment of medication, April 2013

 

Wave 2 Case Studies

Rimonabant

Juhaeri et al, Benefit Risk Wave 2 Case study report Rimonabant, Jan 2012

Rosiglitazone

Philips et al, Benefit Risk Wave 2 Case study report Rosiglitazone, Feb 2013

Natalizumab

Nixon et al, Benefit Risk Wave 2 Case study report Natalizumab, March 2013

Warfarin

Hallgreen et al, Benefit Risk Wave 2 Case study report Warfarin, March 2013

 

Back to Results